Foundation Medicine inks another genomic profiling deal; ImClone vet Lynch heads Blueprint board; Study: Urbanization making people stupid;

 @FierceBiotech: Trending on FierceBiotech.com: 10 Top Women in Biotech 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: Alnylam to pay $75M to settle legal squabble over Tekmira's RNAi delivery tech. Story | Follow @JohnCFierce

 @RyanMFierce: $GILD is looking smart today for buying 7977. Market cap appears to have jumped $6.8B yesterday on news of its 100% SVR with hep C slayer. | Follow @RyanMFierce

> In its second industry pact in two days, Foundation Medicine inked a deal to work with Ariad Pharmaceuticals ($ARIA) on genomic profiling for AP26113, Ariad's experimental dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer and other cancers. Release

> Former ImClone CEO Daniel Lynch is joining Blueprint Medicines as executive chairman. Chris Varma, Ph.D., the founding president and chief executive officer of Blueprint and an entrepreneur-in-residence at Third Rock Ventures, was named permanent president and chief executive officer. Release

> Savara Pharmaceuticals says the FDA granted orphan drug status to AeroVanc (vancomycin hydrochloride inhalation powder) for pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis patients. Release

Pharma News

@FiercePharma: Israeli legal scholars move to sue Teva for shrouding details on executive pay. More | Follow @FiercePharma

> GSK rep wears dunce cap for off-label breach in U.K. Article

> Boycott Roche to open Tamiflu data, critic says. News

Medical Device News

 @FierceMedDev: Chinese device maker Dehaier Medical saw Q3 revenue dip. The reason: an expansion strategy has yet to fully take hold. More | Follow @FierceMedDev

 @MarkHFierce: PerkinElmer snatched up an infectious disease Dx company based in China. More | Follow @MarkHFierce

 @DamianFierce: Hologic took a dive in the last quarter but predicts its $3.8B Gen-Probe buy will brighten the future. Story | Follow @DamianFierce

> Epic Sciences nabs $13M for cancer diagnostics. News

> China's Dehaier Medical Systems' Q3 stagnates as seeds planted for expansion. Report

Biotech Research News

> Harvard's microchip, lined with living cells, mimics disease in preclinical drug test. Report

> Stem cells produce the next potential Alzheimer's treatment. Item

> Kancera credits new drug with slowing pancreatic cancer tumor growth. Article

> Anti-inflammatory drugs that minimize infection risk appear possible. News

> Scientists crack genetic code for rare childhood leukemia variation. Story

Pharma Manufacturing News

> Lundbeck manufacturing starts small in China. Report

> Orchid closing up shop in China. More

> EFCG demands EU inspections of foreign API makers. Article

> FDA confirms Novartis plant, renewing CEO's confidence. Story

> Pilot shows national track and trace 'not insurmountable'. Editor's Corner

And Finally… A new study says that ever since the development of agriculture, humans have been steadily losing their mental and emotional edge as urbanization blunted the genomic machinery that weeded out damaging genetic mutations. Release

 

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.